Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30946361 | 1.00 | PKM (0.40) | PKMALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL30946490 | 0.83 | SMN1; SMN2 (0.41) | PKMALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL30946378 | 0.81 | PKM (0.40) | PKMALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL30946458 | 0.80 | PKM (0.46) | PKMALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL30946439 | 0.80 | PKM (0.46) | PKMALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL26969411 | 0.77 | PTGDR2 (0.40) | PKMALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL29606014 | 0.72 | PTGDR2 (0.42) | POLBKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL27133505 | 0.72 | PTGDR2 (0.42) | POLBKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL20575807 | 0.71 | MAPK14 (0.39) | GAALMNA | |
| SCHEMBL30321193 | 0.71 | MAPK14 (0.39) | GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634161-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024130166-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | disclosed |